《盈利預喜》聯泰控股(00311.HK)料年度轉賺1,000萬至1,200萬美元
聯泰控股(00311.HK)指,由於去年下半年復甦勢頭持續,預期截至去年底止年度錄得純利介乎1,000萬至1,200萬美元(下同),而截至2020年底止年度則錄得虧損淨額約2,800萬元。
董事局認為,預期有關年度由虧轉盈的因素包括隨著相關政府對新冠實行措施放寬,集團的製造工序期內逐步恢復正常;降低營運基礎成本;銷售額逐步回升。
另外,有關為旗下全體僱員的疫苗接種率於2021年年底前達到75%的目標已經達成。目前集團約78%僱員已接種完整兩劑的新冠疫苗,於中國、柬埔寨及菲律賓生產設施的僱員接種率分別約為93%、90%及82%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.